Arvinas - ARVN Stock Forecast, Price & News

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Jefferies Financial Group began coverage on Arvinas in a research note on Tuesday, June 21st. They issued a "hold" rating and a $42.00 target price for the company. Piper Sandler lowered their price target on shares of Arvinas from $116.00 to $76.00 and set an "overweight" rating on the stock in a report on Monday, May 23rd. Cantor Fitzgerald decreased their price target on shares of Arvinas from $140.00 to $115.00 in a report on Friday. Citigroup cut their price objective on shares of Arvinas to $103.00 and set a "buy" rating for the company in a research report on Friday, May 20th. Finally, Wedbush cut shares of Arvinas from an "outperform" rating to a "neutral" rating and set a $43.00 price objective on the stock. in a research note on Monday, May 9th. Three investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, Arvinas has a consensus rating of "Moderate Buy" and an average target price of $86.67.

Arvinas Trading Up 7.8 %

Shares of NASDAQ:ARVN opened at $55.43 on Monday. The stock has a market capitalization of $2.95 billion, a PE ratio of -12.43 and a beta of 2.00. Arvinas has a 12-month low of $34.90 and a 12-month high of $103.53. The stock's fifty day simple moving average is $46.12 and its two-hundred day simple moving average is $56.66.

Arvinas (NASDAQ:ARVN - Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.04) by ($0.28). The business had revenue of $31.30 million during the quarter, compared to analysts' expectations of $23.71 million. Arvinas had a negative net margin of 255.97% and a negative return on equity of 30.11%. Arvinas's revenue for the quarter was up 469.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.03) EPS. On average, equities analysts predict that Arvinas will post -4.36 earnings per share for the current fiscal year.